BACKGROUND Conventional CABG is still the treatment of choice in patients with MVCAD. However, the limitations of
C onventional coronary artery bypass grafting (CABG) is still the current, evidence-based, gold standard treatment of patients with multivessel coronary artery disease (MVCAD) (1, 2) .
The most advantageous part of CABG is the insertion of the left internal mammary artery (LIMA) graft in the left anterior descending artery (LAD) as it is associated with significantly reduced risk of death, myocardial infarction, and recurrent angina and has been proven to provide an excellent long-term patency rate (3) (4) (5) . In contrast, the rate of saphenous vein graft (SVG) patency remains less than optimal with occlusion rates ranging from 6.2% to 30% at 12 months (6) (7) (8) . In non-LAD coronary arteries, the 12-month rate of drug-eluting stent (DES) restenosis and thrombosis after percutaneous coronary intervention (PCI) is lower than the rate of SVG failure (9) . Therefore, PCI with DES in non-LAD targets provides a promising alternative to SVG. All consecutive patients with angiographically confirmed MVD involving the LAD and critical (>70%) lesion in at least 1 (apart from the LAD) major epicardial vessel amenable to both PCI and CABG and referred for conventional surgical revascularization were screened by the local heart team (at least 1 interventional cardiologist with a cardiothoracic surgeon). The heart team checked all the inclusion/ exclusion criteria and the eligibility to perform CABG and PCI in all study participants. It was determined that equivalent anatomic revascularization could be achieved in patients with either CABG or PCI using Xience everolimus-eluting stents (Abbott Vascular, Abbott Park, Illinois) were randomly assigned to undergo 1 of the 2 treatment options. Randomization was conducted in a 1:1 ratio. Figure 1 shows the study flow chart. Gąsior et al.
randomization. The standard of post-intervention care was recommended.
Follow-up assessments were carried out at hospital discharge and at 3, 6, and 9 months after the revascularization procedure. After 12 months, patients were asked to undergo control angiography. Table 1) . Planned revascularization procedures were performed in 93.9% in the HCR group and in all patients in the CABG group and. In the HCR group, a mean of 2.3 stents per patient were placed, whereas in the CABG group, 85.0% of patients were operated on off-pump, using the offpump CABG technique. Complete arterial revascularization was achieved in 24.5% of the patients, and an mean of 2.7 conduits were implanted.
As expected, the MIDCAB procedure was significantly shorter than CABG. The mean time from MID-CAB to PCI was 21 h. Together with DES implantation, the LIMA-LAD was assessed. In 2 patients, it was found to be suboptimal and resulted in subsequent PCI of the LAD in 1, and repeat MIDCAB in a second patient. The HCR group included 6 patients who were converted to sternotomy (intention-to-treat HCR).
These patients did not undergo PCI, as all coronary lesions were addressed with CABG. There were 2 patients who had the first stage of the HRC performed (MIDCAB) but failed PCI (2%). These patients underwent PCI with rotational atherectomy as an auxiliary method at a later time (outside of time planned in the study protocol).
Clinical events occurring during hospitalization and the primary endpoint and its components are presented in Table 2 . There were no significant differences in in-hospital outcome. In 1 patient in the HYBRID group, acute renal failure developed requiring dialysis. The incidence of perioperative myocardial infarction and length of hospitalization were similar.
The cumulative occurrence of major adverse cardiac events was 10.2% and 7.8% for HCR and OPCAB ¼ off-pump coronary artery bypass grafting; PCI ¼ percutaneous coronary intervention.
with an observed difference of 2.4% (95% confidence interval: À5.6% to 10.3%) (Figure 2) . The secondary endpoint, 12-month follow-up angiographic measurements of the patency of grafts and restenosis in revascularized segments, is shown in Table 3 . Our study has shown HCR to be safe in patients with MVCAD, with surgical treatment preceding endovascular. However, in 6 patients (6.1%), conversion to full sternotomy had to be performed. In 4 patients, the conversion was not emergent, but rather planned as the result of either the inability to perform single lung ventilation due to severe chronic obstructive pulmonary disease or the inability to visualize the LIMA due to pleural adhesions. In both cases, there were only port incisions on patients' chests, not thoracotomy incisions. In 2 other patients, endoscopic LIMA harvesting was successful, but the LAD could not be identified once thoracotomy was performed. In 1 patient, there was a significant muscular bridge covering the LAD, whereas in the second patient, there was a large amount of fatty tissue covering the entire myocardium. In both patients, full sternotomy provided better visualization, enabling complete surgical revascularization.
In the last 2 patients, emergent conversion was required. Hemodynamic instability that occurred shortly after LAD occlusion and preparation for intraluminar coronary shunt placement followed by ventricular fibrillation was the main reason for MID-CAB to CABG emergent conversion in the first patient.
In the second patient, significant bleeding that was difficult to manage by endoscopic techniques led to prompt sternotomy. Similar reasons for emergent and planned sternotomy conversions were reported in patients with single-vessel diseases undergoing MIDCAB/endoscopic atraumatic coronary artery bypass (11) . Most importantly, the above-mentioned events were easily managed with median sternotomy, which did not influence early or late outcome. It is noteworthy that the vast majority of patients in the surgical arm underwent off-pump CABG. Although the surgical technique was left to patients' preference, we did not observe significant differences between patients operated on using either method.
There were no off-pump CABG to CABG intraoperative conversions.
As the population of the patients with MVD referred for CABG is growing older with greater comorbidities, less invasive and hazardous techniques should be explored. The intention of the coronary artery hybrid revascularization is to combine the most valuable asset of the standard CABG (i.e., excellent long-term durability of the LIMA-to-LAD graft) with the advantages of PCI (i.e., low rate of stent restenosis and durability of DES superior to SVG patency). Several small retrospective studies have demonstrated that a HCR strategy is safe with low mortality rates (0% to 2%) and event-free survival rates of 83% to 92% at 6 to 12 months of follow-up.
The few series that compared the outcomes of HCR with the standard CABG reported similar outcomes at 30 days and 6 months (12) (13) (14) . The results of these studies are consistent with our findings. To the best of our knowledge, to date, no randomized, controlled trial involving HCR has been published. Therefore, the current practice guidelines recommend HCR as reasonable only if CABG or PCI of the LAD are contraindicated due to severe clinical and/or anatomic reasons or recommend as worthy of consideration instead of CABG or multiple PCIs to improve the overall risk-benefit ratio of these procedures (2).
In the SYNTAX trial, more patients in the CABG group than in the PCI group declined to participate after providing consent, mostly due to the greater invasiveness of CABG (15) . Despite this growing awareness of patients about the possibility of minimally invasive revascularization, the hybrid approach Abbreviations as in Table 1 . LAD ¼ left anterior descending artery; other abbreviations as in Table 1 . 
CONCLUSIONS
The results of our trial show that HCR is feasible in select patients with MVCAD referred for conventional CABG.
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